Roche's Evrysdi, the second treatment for spinal muscular atrophy (SMA) in Korea, began the process of registering insurance benefits eight months after approval.

According to the pharmaceutical industry on the 15th, Roche Korea applied to the HIRA earlier this month for the registration of the oral SMA treatment Evrysdi(Risdiplam).

Evrysdi is the second domestically licensed treatment for spinal muscular dystrophy after Biogen's Spinraza. Although it was approved in November of last year, it has not been officially released in markets yet. A third treatment for spinal muscular dystrophy, Novartis' Zolgensma, has been approved. Novartis completed the application last month using the evalu